查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099047

α粒子發射材料市場－2026-2032年全球市場預測

Alpha Emitters Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，α粒子發射材料市場規模將達到 1,688,880,000 美元，年複合成長率為 10.23%。

主要市場統計數據
基準年 2025 8.537億美元
預計年份：2026年 9.3907億美元
預測年份：2032年 1,688,880,000 美元
複合年成長率 (%) 10.23%

α粒子發射船執行摘要

α放射性核素透過提供高度局部的細胞毒性作用，同時最大限度地減少對周圍健康組織的穿透，正在重新定義精準腫瘤學、核醫學、放射性藥物開發和靶向α放射治療的概念。其臨床意義源自於α粒子的高線性能量轉移率，α粒子能夠誘導惡性細胞中複雜的DNA雙鏈損傷，從而為對傳統外照射、BETA放射性配體療法或全身化療的癌症治療提供新的策略。目前，正在進行科學和臨床評估的主要α放射性核素包括錒-225、鐳-223、砹-211、釷-227、鉛-212、鉍-213和鋱-149。每種核素在半衰期、崩壞系列、螯合、生產和物流等方面都各有不同，需要考慮的因素也各不相同。

α粒子發射段的變革性變化

隨著放射性藥物的創新從核醫學的特定應用領域轉向更廣泛的精準腫瘤學平台，α發射體領域正在經歷一場變革。其中一個關鍵的結構性轉變是從單一療法到整合標靶α發射體治療模式的過渡，這種模式結合了分子影像、病患篩選、病灶劑量測定和基於生物標記的治療設計。這項發展正在完善合理篩選患者、毒性管理以及比較α發射體療法與BETA發射體療法、抗體藥物偶聯物（ADC）、免疫療法和體外放射療法的科學基礎。

人工智慧對α粒子發射材料的累積影響

人工智慧正開始對α粒子放射治療的整個價值鏈產生累積影響，尤其是在標靶發現、放射性藥物設計、影像分析、劑量測定、生產控制和臨床工作流程最佳化等方面。在早期研究中，人工智慧驅動的計算生物學和機器學習模型可以幫助識別腫瘤相關標靶、預測抗原表現模式，並優先篩選具有優異結合、體內攝取和生物分佈特性的配體候選物。在放射化學和製劑開發方面，數據驅動建模可以輔助螯合劑的選擇、穩定性評估和製程最佳化，但所有結果在臨床應用前都需要經過嚴格的實驗檢驗。

關於α粒子發射材料的關鍵區域見解

由於核醫基礎設施的擴建、癌症患者數量的成長以及公共部門對先進癌症治療的濃厚興趣，亞太地區在α放射性核素領域的重要性日益凸顯。日本、韓國、中國、印度和澳洲已在放射性藥物研究、核子反應爐以及臨床核醫學等領域建立了或正在擴大相關能力。該地區的發展得益於對醫院影像和治療設施的投資，但由於監管成熟度、保險報銷體系、放射化學專業知識以及α放射性核素獲取途徑的差異，實際應用情況存在顯著差異。

α發射物質的主要元素分析

雖然北約成員國並非傳統意義上的醫療市場集團，但它們包含許多擁有完善基礎設施的國家，這些基礎設施與先進的核能安全框架、醫用同位素物流能力以及α粒子發射材料的安全處理、運輸和臨床應用密切相關。對於α粒子發射材料而言，北約成員國尤其重要，因為安全的同位素運輸、輻射防護、緊急應變和規範的核能供應鏈是先進醫療系統中引入標靶α療法的基礎。

主要國家對α粒子發射材料的見解

中國正在迅速擴大接收放射性藥物研究、核醫基礎設施和腫瘤服務的能力，使其成為α放射性藥物開發領域具有戰略意義的重要國家。美國是α放射性藥物的中心國家，擁有先進的腫瘤中心、放射性藥物臨床試驗、國家實驗室資源，並積極致力於改善錒-225和其他同位素的生產路線。日本擁有成熟的核醫學能力、對精準腫瘤學的濃厚興趣以及先進的臨床研究基礎設施。另一方面，印度擁有大規模的癌症患者群體、公共核科學實驗室，並且對價格合理的放射性藥物創新日益成長的興趣，這些都為其在該領域的地位提供了支撐，但擴大基礎設施和培養高技能人才仍然是重要的挑戰。

α粒子發射材料產業領導者使用的實用建議

產業領導者應優先考慮同位素供應的韌性，具體措施包括：拓展生產路線、確保合格供應商，以及製定短半衰期放射性核種物流的緊急時應對計畫。對錒-225、鉛-212、砹-211、鐳-223和釷基平台的策略性投資應與檢驗的臨床目標、可擴展的生產控制以及健全的品質保證體系保持一致。此外，各機構也應加強放射化學能力、螯合劑研發、純化方法以及封閉系統操作，以提高可重複性和放射安全性。

調查方法

對α發射體進行執行分析的調查方法是基於檢驗的二手研究、專家解讀以及對公開的科學、臨床、監管和機構資料的系統性檢驗。主要資訊來源包括：關於靶向α療法、放射性核素生產、放射化學、劑量學和核醫學的同行評審文獻；臨床實驗室註冊資訊；監管指導文件；公共衛生和腫瘤學數據；核能安全框架；以及來自經認可的醫療、科學和政府間組織的報告。此調查方法強調證據的品質、資訊來源的可靠性、技術一致性以及與臨床實踐和操作實施的相關性。

結論

α放射性藥物是放射性藥物治療領域技術最先進、臨床應用前景最廣闊的領域之一，有望透過高度標靶的高能量輻射來改善某些癌症的治療效果。其未來的應用取決於各利益相關者能否應對一系列相互關聯的挑戰，包括同位素供應、放射化學、生產品質、臨床證據、劑量測定、安全性、保險報銷以及合格相關人員的取得。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：α粒子發射船市場：依船型分類

  • 錒-225
  • 鋂-241
  • 釙-210
  • 鐳-223

第8章：α粒子發射裝置市場：依設備類型分類

  • 檢測器
    • 充氣式檢測器
    • 閃爍檢測器
    • 固體檢測器
  • 發電機
    • 盒式產生器
    • 列類型產生器
  • 輻射源
    • 密封輻射源
    • 未密封的輻射源

第9章：α粒子發射裝置市場：依發射模式分類

  • 複合材料
  • 液體配方
    • 緩衝液製備
    • 生理食鹽水
  • 密封輻射源
    • 電鍍輻射源
    • 薄膜輻射源

第10章：α粒子發射材料市場：依純度等級分類

  • 大部分
  • 無載體
  • 無載體

第11章：α粒子發射裝置市場：依探測技術分類

  • CdZnTe檢測器
  • 高純鍺檢測器
  • 電離室
  • NaI(Tl)閃爍體
  • 塑膠閃爍體
  • 比例計數器管
  • 固體檢測器

第12章：α粒子發射裝置市場：依應用領域分類

  • 環境監測
    • 大氣監測
    • 土壤取樣
    • 水質監測
  • 工業檢驗
    • 無損檢測
    • 厚度測量
  • 醫療
    • 緩解疼痛
    • 標靶α射線療法
  • 研究與開發
    • 臨床試驗
    • 臨床前研究

第13章：α粒子發射裝置市場：依最終用戶分類

  • 環保組織
  • 醫院和診所
  • 工業無損檢測服務提供者
  • 研究機構

第14章：α粒子發射材料市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第15章：α粒子發射容器市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第16章：α粒子發射材料市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Actinium Pharmaceuticals
  • Alpha 9 Oncology
  • Alpha Tau Medical
  • Ariceum Therapeutics
  • ARTBIO
  • Bayer AG
  • Bristol Myers Squibb
  • BWXT Medical Ltd.
  • Cardinal Health, Inc
  • Curium Pharma, Inc
  • Eckert & Ziegler
  • Fuzionaire Theranostics
  • IBA Radiopharma Solutions
  • IONETIX Corporation
  • Isotopia Molecular Imaging
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings
  • NorthStar Medical Radioisotopes
  • Novartis
  • PanTera
  • Precirix
  • RadioMedix
  • SHINE Technologies
  • Telix Pharmaceuticals
  • TerraPower LLC
Product Code: MRR-742BD517A934

The Alpha Emitters Market is projected to grow by USD 1,688.88 million at a CAGR of 10.23% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 853.70 million
Estimated Year [2026] USD 939.07 million
Forecast Year [2032] USD 1,688.88 million
CAGR (%) 10.23%

Alpha Emitters Executive Summary

Alpha emitters are redefining precision oncology, nuclear medicine, radiopharmaceutical development, and targeted alpha therapy by enabling highly localized cytotoxic effects with limited penetration into surrounding healthy tissue. Their clinical relevance is driven by the high linear energy transfer of alpha particles, which can induce complex DNA double-strand damage in malignant cells and support therapeutic strategies for cancers that are resistant to conventional external beam radiation, beta-emitting radioligand therapy, or systemic chemotherapy. Key alpha-emitting radionuclides under active scientific and clinical evaluation include actinium-225, radium-223, astatine-211, thorium-227, lead-212, bismuth-213, and terbium-149, each presenting distinct half-life, decay-chain, chelation, production, and logistics considerations.

The alpha emitters landscape is shaped by advances in radiochemistry, isotope production, conjugation technologies, theranostics, dosimetry, and nuclear medicine infrastructure. Demand is increasingly influenced by the expansion of prostate cancer radioligand therapy, hematologic malignancy research, solid tumor targeting, and the broader shift toward personalized medicine. At the same time, the sector remains constrained by isotope scarcity, complex manufacturing controls, radiation safety requirements, limited specialist workforce capacity, and the need for harmonized clinical, regulatory, and reimbursement pathways. Industry leaders are prioritizing reliable radionuclide supply, scalable good manufacturing practice production, optimized targeting vectors, and evidence generation to support safe clinical adoption.

Transformative Shifts in the Alpha Emitters Landscape

The alpha emitters ecosystem is undergoing transformative shifts as radiopharmaceutical innovation moves from niche nuclear medicine applications toward broader precision oncology platforms. A major structural change is the transition from single-agent radionuclide therapies to integrated targeted alpha therapy models that combine molecular imaging, patient selection, lesion-level dosimetry, and biomarker-informed treatment design. This evolution is improving the scientific basis for selecting suitable patients, managing toxicity, and comparing alpha-emitting therapeutics with beta emitters, antibody-drug conjugates, immunotherapy, and external radiation approaches.

Supply chain resilience has become one of the most decisive competitive factors. Actinium-225 and other medically relevant alpha emitters require specialized production routes involving accelerators, reactors, generator systems, or decay-chain extraction, and global availability remains dependent on highly regulated nuclear infrastructure. This has pushed stakeholders to invest in diversified isotope production, improved purification methods, validated logistics, and regional radiopharmacy networks. In parallel, regulatory expectations are becoming more sophisticated, with greater scrutiny on radionuclidic purity, daughter isotope behavior, chelator stability, radiation dosimetry, contamination control, and long-term safety monitoring.

Another major shift is the convergence of radiopharmaceutical therapy with biologics, peptides, small molecules, nanocarriers, and companion diagnostics. Alpha emitters are increasingly being paired with tumor-specific ligands that target prostate-specific membrane antigen, somatostatin receptors, CD markers, HER2, mesothelin, and other clinically relevant antigens. This convergence is creating a more complex development environment, where success depends not only on isotope access but also on molecular targeting precision, manufacturing reproducibility, clinical trial design, and multidisciplinary coordination across oncology, radiology, nuclear pharmacy, and radiation safety teams.

Cumulative Impact of Artificial Intelligence on Alpha Emitters

Artificial intelligence is beginning to exert cumulative impact across the alpha emitters value chain, particularly in target discovery, radiopharmaceutical design, image analysis, dosimetry, manufacturing control, and clinical workflow optimization. In early-stage research, AI-enabled computational biology and machine learning models can help identify tumor-associated targets, predict antigen expression patterns, and prioritize ligand candidates with favorable binding, internalization, and biodistribution characteristics. In radiochemistry and formulation development, data-driven modeling can support chelator selection, stability assessment, and process optimization, although all outputs require rigorous experimental validation before clinical use.

In clinical deployment, AI is most relevant to quantitative imaging, lesion segmentation, absorbed dose estimation, treatment planning, and toxicity monitoring. Targeted alpha therapy requires careful understanding of microdosimetry and organ-at-risk exposure, and AI-assisted tools can help standardize interpretation of PET, SPECT, CT, and MRI datasets when integrated with validated medical physics protocols. These capabilities may improve consistency in patient selection, response assessment, and adaptive treatment strategies, especially as clinical datasets expand.

AI also strengthens operational efficiency by supporting batch release analytics, predictive maintenance of production equipment, radiopharmacy scheduling, radiation logistics, inventory planning, and adverse event signal detection. However, its adoption must remain governed by data integrity, model explainability, cybersecurity, regulatory compliance, and clinical accountability. For alpha emitters, the most practical AI advantage is not replacing expert judgment but augmenting multidisciplinary decision-making in a field where isotope availability, short half-lives, complex decay chains, and patient-specific treatment variables demand precision at every step.

Key Regional Insights for Alpha Emitters

Asia-Pacific is becoming increasingly important in alpha emitters due to expanding nuclear medicine infrastructure, rising oncology burden, and strong public-sector interest in advanced cancer treatment. Japan, South Korea, China, India, and Australia have established or expanding capabilities in radiopharmaceutical research, reactor or accelerator-based isotope production, and clinical nuclear medicine. The region's progress is supported by investment in hospital-based imaging and therapy facilities, but adoption varies widely due to differences in regulatory maturity, reimbursement structures, radiochemistry expertise, and access to alpha-emitting radionuclides.

Europe has a highly developed alpha emitters environment anchored by strong nuclear medicine societies, cross-border clinical research, radiochemistry expertise, and regulatory frameworks for advanced medicinal products and radiopharmaceuticals. Germany, France, the United Kingdom, Italy, Spain, and Nordic countries are active in theranostics, alpha therapy trials, hospital radiopharmacy capabilities, and standardized dosimetry practices. The European setting is strengthened by collaborative clinical networks and nuclear safety systems, although isotope supply security and variation in national reimbursement pathways remain key operational considerations.

North America remains a leading region for alpha emitter research, clinical trial activity, radiopharmaceutical manufacturing capability, and regulatory engagement. The United States benefits from advanced academic medical centers, national laboratory infrastructure, accelerator networks, and established oncology trial ecosystems, while Canada contributes through nuclear science expertise and radiopharmaceutical development capacity. The region's strategic focus centers on actinium-225 supply expansion, targeted alpha therapy for prostate cancer and hematologic malignancies, and integration of companion diagnostics into clinical pathways.

Latin America shows selective but meaningful engagement in alpha emitters, supported by nuclear medicine centers in Brazil, Mexico, Argentina, and other countries with experience in diagnostic and therapeutic radioisotopes. Regional progress is shaped by public health system capacity, import dependence for specialized radionuclides, variable reimbursement, and the need for expanded training in radiopharmaceutical therapy. The Middle East is advancing through targeted investments in oncology centers, nuclear medicine departments, and specialized healthcare infrastructure, especially in Gulf economies seeking to expand high-complexity cancer care. Alpha emitter adoption in this region depends on workforce development, radioactive material licensing, regional supply logistics, and referral networks. Africa remains at an earlier stage, with nuclear medicine access uneven across the continent. South Africa and selected North African countries have more established nuclear medicine capabilities, while broader adoption will require investment in radiopharmacy infrastructure, regulatory systems, specialist training, and reliable access to medically relevant radionuclides.

Key Group Insights for Alpha Emitters

NATO countries, while not a healthcare market grouping in the traditional sense, include many nations with advanced nuclear safety frameworks, medical isotope logistics capabilities, and resilient infrastructure relevant to the secure handling, transportation, and clinical use of alpha-emitting materials. This grouping is especially relevant to alpha emitters because secure isotope transport, radiation protection, emergency preparedness, and regulated nuclear supply chains are foundational to targeted alpha therapy deployment across advanced healthcare systems.

G7 countries hold strong advantages in research funding, regulatory sophistication, manufacturing quality systems, nuclear medicine infrastructure, and clinical adoption pathways for radiopharmaceutical therapy. Their alpha emitters activity is supported by established oncology networks, advanced imaging capacity, experienced regulators, and scientific institutions capable of translating radionuclide production and radiochemistry advances into validated clinical protocols. BRICS countries present a diverse but strategically important landscape. China and India are expanding oncology infrastructure and nuclear technology capabilities, Brazil and Russia have established nuclear science foundations, and South Africa provides an important regional base for nuclear medicine in Africa. The group's relevance lies in potential isotope production expansion, cost-sensitive healthcare innovation, and large patient populations suitable for clinical research, though regulatory heterogeneity and infrastructure gaps remain significant.

The European Union has one of the most structured environments for alpha emitter development, supported by coordinated research funding, harmonized medicine regulation, radiopharmaceutical expertise, and strong nuclear medicine networks. EU stakeholders are focusing on clinical evidence generation, isotope security, cross-border trial collaboration, and standardized dosimetry practices. ASEAN's alpha emitters outlook is shaped by a growing cancer burden, expanding tertiary care systems, and uneven nuclear medicine readiness across member states. Countries with stronger hospital infrastructure and regulatory capacity are better positioned to introduce targeted alpha therapy through partnerships, clinical training, and regional radiopharmacy networks. The group's priority is likely to remain capacity building, safe handling protocols, and access to validated radiopharmaceutical supply rather than rapid broad-based deployment.

The GCC is positioned as an emerging hub for advanced oncology services, supported by investments in specialized hospitals, medical imaging, and precision medicine initiatives. For alpha emitters, GCC countries can benefit from centralized healthcare systems and high-complexity care investments, but long-term progress depends on radioactive materials licensing, clinician and radiopharmacist training, and dependable isotope import or production pathways.

Key Country Insights for Alpha Emitters

China is rapidly expanding radiopharmaceutical research, nuclear medicine infrastructure, and oncology service capacity, making it a strategically important country for alpha emitter development. The United States is a central country for alpha emitters, supported by advanced oncology centers, radiopharmaceutical clinical trials, national laboratory resources, and active efforts to improve actinium-225 and other isotope production routes. Japan has mature nuclear medicine capabilities, strong precision oncology interest, and advanced clinical research infrastructure, while India's position is supported by a large cancer patient base, public-sector nuclear science institutions, and growing interest in affordable radiopharmaceutical innovation, though infrastructure expansion and specialist workforce development remain critical.

Germany is highly influential due to its established theranostics ecosystem, extensive nuclear medicine expertise, and strong hospital-based radiopharmacy capabilities. The United Kingdom has strong academic and clinical research capabilities in radiopharmaceutical therapy, with ongoing emphasis on clinical trial infrastructure and nuclear medicine capacity. Australia benefits from established nuclear science assets, radiopharmaceutical production expertise, and participation in international clinical research. France combines nuclear sector expertise with clinical oncology and radiopharmaceutical research strengths, while South Korea combines advanced hospital systems, strong biotechnology capabilities, and growing nuclear medicine interest, positioning it as a meaningful contributor to targeted alpha therapy development in Asia-Pacific.

Italy and Spain are increasingly active in theranostics and nuclear oncology, supported by specialist centers and European clinical collaboration. Canada contributes through nuclear research capabilities, radiopharmaceutical expertise, and established nuclear medicine practice. Russia has substantial nuclear science infrastructure and experience with radioisotope technologies, supporting its relevance in radionuclide research and production. Brazil has one of Latin America's more developed nuclear medicine environments, and its future role depends on strengthening local production, reimbursement access, and specialist training. Mexico's opportunity is tied to expanding access to advanced oncology diagnostics and therapy within major urban healthcare systems.

Actionable Recommendations for Alpha Emitters Industry Leaders

Industry leaders should prioritize isotope supply resilience by diversifying production routes, securing qualified suppliers, and developing contingency plans for short-lived radionuclide logistics. Strategic investment in actinium-225, lead-212, astatine-211, radium-223, and thorium-based platforms should be aligned with validated clinical targets, scalable manufacturing controls, and robust quality assurance systems. Organizations should also strengthen radiochemistry capabilities, chelator development, purification methods, and closed-system handling to improve reproducibility and radiation safety.

Clinical development strategies should integrate companion imaging, patient selection biomarkers, individualized dosimetry, and standardized response criteria from the outset. Multidisciplinary collaboration among nuclear medicine physicians, oncologists, radiopharmacists, medical physicists, radiation safety officers, and regulatory specialists is essential for safe adoption. Leaders should build evidence packages that address efficacy, toxicity, quality of life, operational feasibility, and long-term monitoring requirements.

To accelerate readiness, organizations should invest in workforce training, digital infrastructure, AI-assisted imaging and dosimetry tools, and harmonized standard operating procedures. Partnerships with hospitals, isotope producers, academic centers, and regulatory stakeholders can reduce development risk and improve trial execution. Commercial strategies should avoid relying solely on scientific differentiation and instead address real-world barriers, including reimbursement, referral pathways, radiopharmacy capacity, patient travel burden, and radioactive waste management.

Research Methodology

The research methodology for alpha emitters executive analysis relies on verified secondary research, expert interpretation, and structured validation of publicly available scientific, clinical, regulatory, and institutional sources. Core inputs include peer-reviewed literature on targeted alpha therapy, radionuclide production, radiochemistry, dosimetry, and nuclear medicine; clinical trial registries; regulatory guidance documents; public health and oncology data; nuclear safety frameworks; and reports from recognized medical, scientific, and intergovernmental bodies. The methodology emphasizes evidence quality, source credibility, technical consistency, and relevance to real-world clinical and operational adoption.

Data synthesis is conducted through triangulation across scientific publications, regulatory records, clinical development activity, isotope production disclosures, and healthcare infrastructure indicators. Particular attention is given to radionuclide characteristics, production feasibility, chelation stability, targeting mechanisms, safety considerations, and regional nuclear medicine capacity. Insights are reviewed to exclude unsupported claims, speculative financial projections, market sizing, market share, and forecasting. The approach is designed to provide decision-ready qualitative intelligence on alpha emitters while maintaining scientific accuracy and compliance with evidence-based reporting standards.

Conclusion

Alpha emitters represent one of the most technically sophisticated and clinically promising areas of radiopharmaceutical therapy, with potential to improve outcomes in selected cancers through highly targeted, high-energy radiation delivery. Their future adoption will depend on the ability of stakeholders to solve interconnected challenges involving isotope supply, radiochemistry, manufacturing quality, clinical evidence, dosimetry, safety, reimbursement, and specialist workforce readiness.

The sector is moving toward more integrated theranostic models where molecular targeting, diagnostic imaging, artificial intelligence, and patient-specific treatment planning work together to support precision oncology. Regions and countries with strong nuclear medicine infrastructure, regulatory clarity, and coordinated clinical research networks are best positioned to advance targeted alpha therapy responsibly. For industry leaders, the immediate priority is to convert scientific promise into reliable, scalable, and clinically validated solutions that meet the practical needs of healthcare systems and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Alpha Emitters Market, by Emitter Type

  • 7.1. Introduction
  • 7.2. Actinium-225
  • 7.3. Americium-241
  • 7.4. Polonium-210
  • 7.5. Radium-223

8. Alpha Emitters Market, by Equipment Type

  • 8.1. Introduction
  • 8.2. Detectors
    • 8.2.1. Gas-Filled Detectors
    • 8.2.2. Scintillation Detectors
    • 8.2.3. Solid State Detectors
  • 8.3. Generators
    • 8.3.1. Cartridge Generators
    • 8.3.2. Column Generators
  • 8.4. Sources
    • 8.4.1. Sealed Sources
    • 8.4.2. Unsealed Sources

9. Alpha Emitters Market, by Delivery Mode

  • 9.1. Introduction
  • 9.2. Composite Materials
  • 9.3. Liquid Solutions
    • 9.3.1. Buffered Solutions
    • 9.3.2. Saline Solutions
  • 9.4. Sealed Sources
    • 9.4.1. Electroplated Sources
    • 9.4.2. Thin-Film Sources

10. Alpha Emitters Market, by Purity Grade

  • 10.1. Introduction
  • 10.2. Bulk
  • 10.3. Carrier-Free
  • 10.4. No-Carrier-Added

11. Alpha Emitters Market, by Detection Technique

  • 11.1. Introduction
  • 11.2. CdZnTe Detectors
  • 11.3. HPGe Detectors
  • 11.4. Ionization Chambers
  • 11.5. NaI(Tl) Scintillators
  • 11.6. Plastic Scintillators
  • 11.7. Proportional Counters
  • 11.8. Solid State Detectors

12. Alpha Emitters Market, by Application

  • 12.1. Introduction
  • 12.2. Environmental Monitoring
    • 12.2.1. Air Monitoring
    • 12.2.2. Soil Sampling
    • 12.2.3. Water Monitoring
  • 12.3. Industrial Testing
    • 12.3.1. Non-Destructive Testing
    • 12.3.2. Thickness Gauging
  • 12.4. Medical Therapy
    • 12.4.1. Pain Palliation
    • 12.4.2. Targeted Alpha Therapy
  • 12.5. Research & Development
    • 12.5.1. Clinical Trials
    • 12.5.2. Preclinical Research

13. Alpha Emitters Market, by End User

  • 13.1. Introduction
  • 13.2. Environmental Agencies
  • 13.3. Hospitals & Clinics
  • 13.4. Industrial Non-Destructive Testing Providers
  • 13.5. Research Institutes

14. Alpha Emitters Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. Europe
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Africa
  • 14.6. Middle East

15. Alpha Emitters Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. BRICS
  • 15.4. European Union
  • 15.5. ASEAN
  • 15.6. GCC

16. Alpha Emitters Market, by Country

  • 16.1. China
  • 16.2. United States
  • 16.3. Japan
  • 16.4. India
  • 16.5. Germany
  • 16.6. United Kingdom
  • 16.7. Australia
  • 16.8. France
  • 16.9. South Korea
  • 16.10. Italy
  • 16.11. Canada
  • 16.12. Russia
  • 16.13. Brazil
  • 16.14. Mexico
  • 16.15. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Actinium Pharmaceuticals
  • 18.2. Alpha 9 Oncology
  • 18.3. Alpha Tau Medical
  • 18.4. Ariceum Therapeutics
  • 18.5. ARTBIO
  • 18.6. Bayer AG
  • 18.7. Bristol Myers Squibb
  • 18.8. BWXT Medical Ltd.
  • 18.9. Cardinal Health, Inc
  • 18.10. Curium Pharma, Inc
  • 18.11. Eckert & Ziegler
  • 18.12. Fuzionaire Theranostics
  • 18.13. IBA Radiopharma Solutions
  • 18.14. IONETIX Corporation
  • 18.15. Isotopia Molecular Imaging
  • 18.16. ITM Isotope Technologies Munich SE
  • 18.17. Lantheus Holdings
  • 18.18. NorthStar Medical Radioisotopes
  • 18.19. Novartis
  • 18.20. PanTera
  • 18.21. Precirix
  • 18.22. RadioMedix
  • 18.23. SHINE Technologies
  • 18.24. Telix Pharmaceuticals
  • 18.25. TerraPower LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA EMITTERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ALPHA EMITTERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ALPHA EMITTERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ALPHA EMITTERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ALPHA EMITTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ALPHA EMITTERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ALPHA EMITTERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ALPHA EMITTERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL ALPHA EMITTERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ALPHA EMITTERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ALPHA EMITTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACTINIUM-225 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACTINIUM-225 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACTINIUM-225 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMERICIUM-241 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMERICIUM-241 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMERICIUM-241 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POLONIUM-210 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POLONIUM-210 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POLONIUM-210 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIUM-223 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIUM-223 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIUM-223 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GAS-FILLED DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GAS-FILLED DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GAS-FILLED DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SCINTILLATION DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SCINTILLATION DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SCINTILLATION DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENERATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENERATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENERATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARTRIDGE GENERATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARTRIDGE GENERATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARTRIDGE GENERATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLUMN GENERATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLUMN GENERATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLUMN GENERATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEALED SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SEALED SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEALED SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UNSEALED SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UNSEALED SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UNSEALED SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPOSITE MATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOSITE MATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPOSITE MATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BUFFERED SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BUFFERED SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BUFFERED SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SALINE SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SALINE SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SALINE SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEALED SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEALED SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SEALED SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ELECTROPLATED SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ELECTROPLATED SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ELECTROPLATED SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIN-FILM SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIN-FILM SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIN-FILM SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BULK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BULK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BULK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARRIER-FREE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARRIER-FREE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARRIER-FREE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NO-CARRIER-ADDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NO-CARRIER-ADDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NO-CARRIER-ADDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CDZNTE DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CDZNTE DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CDZNTE DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HPGE DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HPGE DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HPGE DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IONIZATION CHAMBERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IONIZATION CHAMBERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IONIZATION CHAMBERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NAI(TL) SCINTILLATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NAI(TL) SCINTILLATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NAI(TL) SCINTILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PLASTIC SCINTILLATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASTIC SCINTILLATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLASTIC SCINTILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROPORTIONAL COUNTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROPORTIONAL COUNTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROPORTIONAL COUNTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SOLID STATE DETECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENVIRONMENTAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENVIRONMENTAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENVIRONMENTAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AIR MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AIR MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL AIR MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SOIL SAMPLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SOIL SAMPLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SOIL SAMPLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL WATER MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL WATER MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL WATER MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INDUSTRIAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-DESTRUCTIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NON-DESTRUCTIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-DESTRUCTIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL THICKNESS GAUGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL THICKNESS GAUGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL THICKNESS GAUGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MEDICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MEDICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MEDICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PAIN PALLIATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PAIN PALLIATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PAIN PALLIATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED ALPHA THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED ALPHA THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED ALPHA THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PRECLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENVIRONMENTAL AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENVIRONMENTAL AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENVIRONMENTAL AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INDUSTRIAL NON-DESTRUCTIVE TESTING PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INDUSTRIAL NON-DESTRUCTIVE TESTING PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INDUSTRIAL NON-DESTRUCTIVE TESTING PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. G7 ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 288. G7 ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 289. G7 ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 291. G7 ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. GCC ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 344. GCC ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. GCC ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 347. GCC ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 348. GCC ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 349. GCC ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 350. GCC ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 351. GCC ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 352. GCC ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 353. GCC ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 354. GCC ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 355. GCC ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 356. GCC ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 357. GCC ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 358. GCC ALPHA EMITTERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 359. GCC ALPHA EMITTERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 360. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 361. CHINA ALPHA EMITTERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. CHINA ALPHA EMITTERS MARKET SIZE, BY EMITTER TYPE, 2018-2032 (USD MILLION)
  • TABLE 363. CHINA ALPHA EMITTERS MARKET SIZE, BY EQUIPMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. CHINA ALPHA EMITTERS MARKET SIZE, BY DETECTORS, 2018-2032 (USD MILLION)
  • TABLE 365. CHINA ALPHA EMITTERS MARKET SIZE, BY GENERATORS, 2018-2032 (USD MILLION)
  • TABLE 366. CHINA ALPHA EMITTERS MARKET SIZE, BY SOURCES, 2018-2032 (USD MILLION)
  • TABLE 367. CHINA ALPHA EMITTERS MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 368. CHINA ALPHA EMITTERS MARKET SIZE, BY LIQUID SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 369. CHINA ALPHA EMITTERS MARKET SIZE, BY SEALED SOURCES, 2018-2032 (USD MILLION)
  • TABLE 370. CHINA ALPHA EMITTERS MARKET SIZE, BY PURITY GRADE, 2018-2032 (USD MILLION)
  • TABLE 371. CHINA ALPHA EMITTERS MARKET SIZE, BY DETECTION TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 372. CHINA ALPHA EMITTERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 373. CHINA ALPHA EMITTERS MARKET SIZE, BY ENVIRONMENTAL MONITORING, 2018-2032 (USD MILLION)
  • TABLE 374. CHINA ALPHA EMITTERS MARKET SIZE, BY INDUSTRIAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 375. CHINA ALPHA EMITTERS MARKET SIZE, BY MEDICAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 376. CHINA ALPHA